Akili, Inc. (AKLI)
Jul 2, 2024 - AKLI was delisted (reason: acquired by Virtual Therapeutics)
0.4331
+0.0010 (0.25%)
Inactive · Last trade price on Jul 1, 2024
AKLI's stock price has decreased by -60.98% in the past year and price targets may not have had time to catch up.

Akili Analyst Ratings

Total Analysts
1
Consensus Rating
Buy
Price Target
$4.00
Upside
+823.57%

Ratings History

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Credit Suisse
Credit Suisse
Buy
Reiterates
$4
BuyReiterates$4+823.57%Aug 11, 2023
Morgan Stanley
Morgan Stanley
Hold
Maintains
$2$3
HoldMaintains$2$3+592.68%Jan 25, 2023
Morgan Stanley
Morgan Stanley
Hold
Initiates
$2
HoldInitiates$2+361.79%Dec 28, 2022
B of A Securities
B of A Securities
Hold
Initiates
$2
HoldInitiates$2+361.79%Nov 18, 2022
Credit Suisse
Credit Suisse
Buy
Maintains
$4$4.5
BuyMaintains$4$4.5+939.02%Nov 15, 2022
Credit Suisse
Credit Suisse
Buy
Initiates
$5
BuyInitiates$5+1,054.47%Oct 25, 2022
Cowen & Co.
Cowen & Co.
Buy
Initiates
n/a
BuyInitiatesn/an/aSep 6, 2022